Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophag...

por Lorenzen, S, Pauligk, C, Homann, N, Schmalenberg, H, Jäger, E, Al-Batran, S-E
Publicado 2013

Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials

por Al-Batran, S-E, Güntner, M, Pauligk, C, Scholz, M, Chen, R, Beiss, B, Stopatschinskaja, S, Lerbs, W, Harbeck, N, Jäger, E
Publicado 2010

Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial

por Atmaca, A, Al-Batran, S-E, Maurer, A, Neumann, A, Heinzel, T, Hentsch, B, Schwarz, S E, Hövelmann, S, Göttlicher, M, Knuth, A, Jäger, E
Publicado 2007

New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma

por Wedel, S A, Sparatore, A, Soldato, P D, Al-Batran, S-E, Atmaca, A, Juengel, E, Hudak, L, Jonas, D, Blaheta, R A
Publicado 2008

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

por Haense, N., Atmaca, A., Pauligk, C., Steinmetz, K., Marmé, F., Haag, G. M., Rieger, M., Ottmann, O. G., Ruf, P., Lindhofer, H., Al-Batran, S.-E.
Publicado 2016

The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial

por Al-Batran, S-E, Bischoff, J, von Minckwitz, G, Atmaca, A, Kleeberg, U, Meuthen, I, Morack, G, Lerbs, W, Hecker, D, Sehouli, J, Knuth, A, Jager, E
Publicado 2006

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone

por Wimberger, P., Gilet, H., Gonschior, A-K., Heiss, M. M., Moehler, M., Oskay-Oezcelik, G., Al-Batran, S-E., Schmalfeldt, B., Schmittel, A., Schulze, E., Parsons, S. L.
Publicado 2012

A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology

por Al-Batran, S.-E., Mueller, D.W., Rafiyan, M.-R., Kiselicki, D., Atmaca, A., Habibzada, T., Mueller, C., Brignone, C., Triebel, F., Loose, M., Schaaf, M., Sookthai, D., Eickhoff, R., Jaeger, E., Goetze, T.O.
Publicado 2023

A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer

por Atmaca, A, Al-Batran, S-E, Werner, D, Pauligk, C, Güner, T, Koepke, A, Bernhard, H, Wenzel, T, Banat, A-G, Brueck, P, Caca, K, Prasnikar, N, Kullmann, F, Günther Derigs, H, Koenigsmann, M, Dingeldein, G, Neuhaus, T, Jäger, E
Publicado 2013

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial

por Huebner, G, Link, H, Kohne, C H, Stahl, M, Kretzschmar, A, Steinbach, S, Folprecht, G, Bernhard, H, Al-Batran, S E, Schoffski, P, Burkart, C, Kullmann, F, Otremba, B, Menges, M, Hoffmann, M, Kaiser, U, Aldaoud, A, Jahn, A
Publicado 2009

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated ga...

por Al-Batran, S.-E., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O. N., Kim, T.-Y., Cunningham, D., Rougier, P., Muro, K., Liepa, A. M., Chandrawansa, K., Emig, M., Ohtsu, A., Wilke, H.
Publicado 2016

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

por Türeci, O, Sahin, U, Schulze-Bergkamen, H, Zvirbule, Z, Lordick, F, Koeberle, D, Thuss-Patience, P, Ettrich, T, Arnold, D, Bassermann, F, Al-Batran, S E, Wiechen, K, Dhaene, K, Maurus, D, Gold, M, Huber, C, Krivoshik, A, Arozullah, A, Park, J W, Schuler, M
Publicado 2019

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: p...

por Bang, Y -J, Ruiz, E Yañez, Van Cutsem, E, Lee, K -W, Wyrwicz, L, Schenker, M, Alsina, M, Ryu, M -H, Chung, H -C, Evesque, L, Al-Batran, S -E, Park, S H, Lichinitser, M, Boku, N, Moehler, M H, Hong, J, Xiong, H, Hallwachs, R, Conti, I, Taieb, J
Publicado 2018